拉福拉病的临床过程和管理挑战:阿普利亚队列中的叙述分析
Giuseppe d'Orsi1, Maria Teresa Di Claudio2, Antonella Liantonio3
1Neurology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini, 1, 71013, San Giovanni Rotondo, FG, Italy. g.dorsi@operapadrepio.it.
Orphanet journal of rare diseases
|August 22, 2025
概括
拉福拉病 (LD) 是一种罕见的神经退行性疾病. 这项研究概述了其临床阶段,并强调需要多学科的护理和家庭支持,特别是在晚期.
科学领域:
- 神经科学
- 遗传学
- 罕见疾病
背景情况:
- 拉福拉病 (LD) 是一种极为罕见的自体衰退性神经退行性疾病.
- 通过拉福拉体积累的特征,导致,痴呆和.
- 在意大利南部的阿普利亚地区明显更高的患病率需要进一步调查.
研究的目的:
- 描述拉福拉病的临床过程和管理挑战.
- 分析意大利南部阿普利亚地区的一组LD.
- 确定不同的电临床阶段和有效的管理策略.
主要方法:
- 临床,脑电图和管理数据的回顾性分析.
- 涉及六个未经确认的LD诊断的家庭 (2010-2024年).
- 收集有关人口统计,临床表现,治疗,进展和结果的数据.
主要成果:
- 确定了三个电临床阶段:呈现症状,渐进性神经退行和终端.
- 晚期的治疗是具有挑战性的,需要对耐性和医疗并发症进行多学科治疗.
- 家庭护理与专业支持在减少住院的过程中至关重要.
结论:
- 早期诊断和多学科治疗对于拉福拉病至关重要.
- 有效的家庭护理对于晚期患者的健康至关重要.
- 需要进一步研究遗传/环境因素和早期生物标志物.
更多相关视频
相关概念视频
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Animal Mitochondrial Genetics
8.0K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
8.0K
Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703


